{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T21:10:01Z","timestamp":1761858601460,"version":"build-2065373602"},"reference-count":39,"publisher":"Ovid Technologies (Wolters Kluwer Health)","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:p>Transthyretin (ATTR) cardiac amyloidosis is an infiltrative, restrictive cardiomyopathy that causes heart failure with both preserved and reduced ejection fraction. Historically considered a disease without treatment, the approval of transthyretin stabilizers brought about a major shift in the paradigm. Following closely on the heels of tafamidis, the United States Food and Drug Administration approved acoramidis for patients with ATTR cardiac amyloidosis in 2024. Similar approvals were also seen across Japan, the European Union, and the United Kingdom. Acoramidis is a highly potent transthyretin (TTR) stabilizer. The mechanism of action of acoramidis centers around its interaction with the unique ultrastructure of the TTR tetramer. The TTR tetramer comprises 2 linked homodimers that are stabilized by the binding of a thyroxine molecule. Acoramidis mimics the transthyretin-stabilizing T119M mutation, stabilizing the tetramer by 2 mechanisms. First, by binding to the TTR thyroxine-binding site to serve as a bridging molecule between the 2 dimeric subcomponents of the tetramer, it dramatically improves its kinetic stability. Second, it engages in hydrogen bond-based enthalpic binding. Cumulatively, this helps achieve TTR stabilization to the order of &gt;90%. In clinical trials, acoramidis has demonstrated a robust safety profile. Acoramidis also improved clinical outcomes such as all-cause mortality and cardiovascular hospitalizations; improved biomechanistic parameters such as 6-minute walk distances, n-terminal pro B-type natriuretic peptide levels, stabilization of myocardial thickness; as well as improved patient-reported outcomes through improved Kansas City Cardiomyopathy Questionnaire scores. The results of the ACT-EARLY trial exploring the preventive benefits of acoramidis are eagerly awaited.<\/jats:p>","DOI":"10.1097\/crd.0000000000001074","type":"journal-article","created":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T21:00:24Z","timestamp":1761858024000},"update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Acoramidis for the Treatment of Transthyretin Cardiac Amyloidosis"],"prefix":"10.1097","author":[{"given":"Ashwin A.","family":"Pillai","sequence":"first","affiliation":[{"name":"Department of Cardiology, Virginia Commonwealth University, Richmond, VA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Balaphanidhar","family":"Mogga","sequence":"additional","affiliation":[{"name":"Department of Medicine, Lundquist Institute, Harbor-University of California Los Angeles Medical Center, Los Angeles, CA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Siddhant","family":"Passey","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Connecticut, Farmington, CT"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William H.","family":"Frishman","sequence":"additional","affiliation":[{"name":"Department of Medicine, Westchester Medical Center and New York Medical College, Valhalla, NY"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wilbert S.","family":"Aronow","sequence":"additional","affiliation":[{"name":"Departments of Cardiology and Medicine, Westchester Medical Center and New York Medical College, Valhalla, NY."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2025,10,20]]},"reference":[{"key":"R1-20251030","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1056\/NEJMoa2305434","article-title":"Efficacy and safety of acoramidis in transthyretin amyloid cardiomyopathy.","volume":"390","author":"Gillmore","year":"2024","journal-title":"N Engl J Med"},{"key":"R2-20251030","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.jaccao.2021.07.010","article-title":"Electrophysiological manifestations of cardiac amyloidosis: JACC: cardiooncology state-of-the-art review.","volume":"3","author":"Hartnett","year":"2021","journal-title":"JACC CardioOncol"},{"key":"R4-20251030","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1002\/cpdd.700","article-title":"First\u2010in\u2010human study of AG10, a novel, oral, specific, selective, and potent transthyretin stabilizer for the treatment of transthyretin amyloidosis: a phase 1 safety, tolerability, pharmacokinetic, and pharmacodynamic study in healthy adult volunteers.","volume":"9","author":"Fox","year":"2020","journal-title":"Clin Pharmacol Drug Dev"},{"key":"R5-20251030","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/s13023-025-03547-0","article-title":"Epidemiology of transthyretin (ATTR) amyloidosis: a systematic literature review.","volume":"20","author":"Delgado","year":"2025","journal-title":"Orphanet J Rare Dis"},{"issue":"18_Supplement_1","key":"R6-20251030","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1016\/S0735-1097(21)02243-9","article-title":"Use of commercial claims data to estimate transthyretin-amyloid cardiomyopathy prevalence and incidence in the us.","volume":"77","author":"Brown","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"R7-20251030","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1161\/CIRCULATIONAHA.122.060852","article-title":"Impact of earlier diagnosis in cardiac ATTR amyloidosis over the course of 20 years.","volume":"146","author":"Ioannou","year":"2022","journal-title":"Circulation"},{"issue":"Suppl_1","key":"R8-20251030","doi-asserted-by":"crossref","first-page":"A17122","DOI":"10.1161\/circ.148.suppl_1.17122","article-title":"Abstract 17122: role of a dedicated program in early recognition and treatment of transthyretin cardiac amyloidosis.","volume":"148","author":"Pillai","year":"2023","journal-title":"Circulation"},{"key":"R9-20251030","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.cardfail.2024.10.309","article-title":"Lessons learned from the cardiac amyloidosis management program: the Hartford experience.","volume":"31","author":"Pillai","year":"2025","journal-title":"J Card Fail"},{"key":"R10-20251030","first-page":"e7","article-title":"The role of sodium-glucose cotransporter-2 inhibitors in adults with transthyretin cardiac amyloidosis: a single-center retrospective cohort study.","volume":"16","author":"Pillai","year":"2725","journal-title":"Cureus"},{"key":"R11-20251030","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.cardfail.2024.10.020","article-title":"Experience with long-term inotrope therapy in advanced cardiac amyloidosis management.","volume":"31","author":"Pillai","year":"2025","journal-title":"J Card Fail"},{"key":"R12-20251030","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1007\/s11739-022-02944-8","article-title":"SGLT2i in patients with transthyretin cardiac amyloidosis, a well-tolerated option for heart failure treatment? Results from a small, real-world, patients series.","volume":"17","author":"Zampieri","year":"2022","journal-title":"Intern Emerg Med"},{"key":"R13-20251030","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1056\/NEJMoa1805689","article-title":"Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy.","volume":"379","author":"Maurer","year":"2018","journal-title":"N Engl J Med"},{"key":"R14-20251030","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1186\/s13023-023-02824-0","article-title":"Tafamidis decreased cardiac amyloidosis deposition in patients with Ala97Ser hereditary transthyretin cardiomyopathy: a 12-month follow-up cohort study.","volume":"18","author":"Tsai","year":"2023","journal-title":"Orphanet J Rare Dis"},{"key":"R16-20251030","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.1016\/j.jacc.2025.03.542","article-title":"Early increase in serum transthyretin by acoramidis independently predicts improved survival in TTR amyloid cardiomyopathy.","volume":"85","author":"Maurer","year":"2025","journal-title":"J Am Coll Cardiol"},{"issue":"suppl_21","key":"R17-20251030","first-page":"A15977","article-title":"Abstract 15977: a stabilizing variant in Transthyretin, T119M, and risk of ischemic vascular disease.","volume":"126","author":"Hornstrup","year":"2012","journal-title":"Circulation"},{"key":"R18-20251030","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.3390\/biomedicines10081906","article-title":"The journey of human transthyretin: synthesis, structure stability, and catabolism.","volume":"10","author":"Sanguinetti","year":"2022","journal-title":"Biomedicines"},{"key":"R19-20251030","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/0009-8981(68)90173-3","article-title":"Influence of age and sex on prealbumin levels.","volume":"20","author":"Stabilini","year":"1968","journal-title":"Clin Chim Acta"},{"key":"R20-20251030","doi-asserted-by":"crossref","first-page":"572","DOI":"10.3945\/an.115.008508","article-title":"Plasma transthyretin as a biomarker of lean body mass and catabolic states12.","volume":"6","author":"Ingenbleek","year":"2015","journal-title":"Adv Nutr"},{"key":"R21-20251030","doi-asserted-by":"crossref","first-page":"e004000","DOI":"10.1161\/CIRCHEARTFAILURE.117.004000","article-title":"Utility of serum transthyretin as a prognostic indicator and predictor of outcome in cardiac amyloid disease associated with wild-type transthyretin.","volume":"11","author":"Hanson","year":"2018","journal-title":"Circ Heart Fail"},{"key":"R22-20251030","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1097\/00000441-198501000-00003","article-title":"Lowered prealbumin levels in patients with familial amyloid polyneuropathy (FAP) and their non-affected but at risk relatives.","volume":"289","author":"Skinner","year":"1985","journal-title":"Am J Med Sci"},{"key":"R25-20251030","doi-asserted-by":"crossref","first-page":"5008","DOI":"10.1038\/s41467-019-13038-z","article-title":"Cryo-EM structure of a transthyretin-derived amyloid fibril from a patient with hereditary ATTR amyloidosis.","volume":"10","author":"Schmidt","year":"2019","journal-title":"Nat Commun"},{"key":"R27-20251030","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1007\/s40119-025-00422-8","article-title":"Transthyretin kinetic stabilizers for ATTR amyloidosis.","volume":"14","author":"Kelly","year":"2025","journal-title":"Cardiol Ther"},{"key":"R28-20251030","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1016\/j.jacc.2024.11.042","article-title":"Efficacy of acoramidis on all-cause mortality and cardiovascular hospitalization in transthyretin amyloid cardiomyopathy.","volume":"85","author":"Judge","year":"2025","journal-title":"J Am Coll Cardiol"},{"key":"R29-20251030","article-title":"Antibody ALXN2220 (Formerly NI006) for the treatment of transthyretin cardiac amyloidosis","author":"Pillai","year":"2025","journal-title":"Cardiol Rev"},{"key":"R33-20251030","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1007\/s40119-025-00402-y","article-title":"Rationale and design of ANTHOLOGY: An ATTR amyloidosis real-world evidence program aiming to address gaps in amyloidosis care.","volume":"14","author":"Gillmore","year":"2025","journal-title":"Cardiol Ther"},{"key":"R36-20251030","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.jacc.2019.03.012","article-title":"Transthyretin stabilization by AG10 in symptomatic transthyretin amyloid cardiomyopathy.","volume":"74","author":"Judge","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"R37-20251030","doi-asserted-by":"crossref","first-page":"e012135","DOI":"10.1161\/CIRCHEARTFAILURE.124.012135","article-title":"Effect of acoramidis on myocardial structure and function in transthyretin amyloid cardiomyopathy: insights from the ATTRibute-CM cardiac magnetic resonance (CMR) substudy.","volume":"17","author":"Razvi","year":"2024","journal-title":"Circ Heart Fail"},{"key":"R38-20251030","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1080\/13506129.2020.1758658","article-title":"Transthyretin-stabilising mutation T119M is not associated with protection against vascular disease or death in the UK Biobank.","volume":"27","author":"Parker","year":"2020","journal-title":"Amyloid"},{"key":"R39-20251030","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1161\/CIRCULATIONAHA.124.072771","article-title":"Long-term efficacy and safety of acoramidis in ATTR-CM: initial report from the open-label extension of the ATTRibute-CM trial.","volume":"151","author":"Judge","year":"2025","journal-title":"Circulation"},{"key":"R40-20251030","doi-asserted-by":"crossref","first-page":"10787","DOI":"10.1038\/ncomms10787","article-title":"Repositioning tolcapone as a potent inhibitor of transthyretin amyloidogenesis and associated cellular toxicity.","volume":"7","author":"Sant\u2019Anna","year":"2016","journal-title":"Nat Commun"},{"key":"R41-20251030","doi-asserted-by":"crossref","first-page":"16145","DOI":"10.3390\/ijms232416145","article-title":"Oral therapy for the treatment of transthyretin-related amyloid cardiomyopathy.","volume":"23","author":"Nuvolone","year":"2022","journal-title":"Int J Mol Sci"},{"key":"R42-20251030","doi-asserted-by":"crossref","first-page":"109","DOI":"10.2147\/CIA.S3787","article-title":"Tolcapone: review of its pharmacology and use as adjunctive therapy in patients with Parkinson\u2019s disease.","volume":"4","author":"Truong","year":"2009","journal-title":"Clin Interv Aging"},{"key":"R44-20251030","doi-asserted-by":"crossref","first-page":"81","DOI":"10.2165\/00003088-199120010-00006","article-title":"Pharmacokinetics of diflunisal in patients.","volume":"20","author":"Nuernberg","year":"1991","journal-title":"Clin Pharmacokinet"},{"key":"R47-20251030","first-page":"e202304","article-title":"Lessons from the first-in-human in vivo CRISPR\/Cas9 editing of the TTR gene by NTLA-2001 trial in patients with transthyretin amyloidosis with cardiomyopathy.","volume":"2023","author":"Kotit","year":"2023","journal-title":"Glob Cardiol Sci Pract"},{"key":"R48-20251030","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1056\/NEJMoa2409134","article-title":"Vutrisiran in patients with transthyretin amyloidosis with cardiomyopathy.","volume":"392","author":"Fontana","year":"2025","journal-title":"N Engl J Med"},{"key":"R49-20251030","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1016\/j.cardfail.2023.11.016","article-title":"Effect of eplontersen on cardiac structure and function in patients with hereditary transthyretin amyloidosis.","volume":"30","author":"Masri","year":"2024","journal-title":"J Card Fail"},{"issue":"2Part A","key":"R50-20251030","first-page":"118","article-title":"False Negative 99mTc-DPD Scintigraphy in pVal50Met (Val30Met) Hereditary Transthyretin Amyloidosis.","volume":"6","author":"Redzepi","year":"2023","journal-title":"CJC Open"},{"key":"R51-20251030","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1016\/j.jcmg.2019.10.015","article-title":"Low sensitivity of bone scintigraphy in detecting Phe64Leu mutation-related transthyretin cardiac amyloidosis.","volume":"13","author":"Musumeci","year":"2020","journal-title":"JACC Cardiovasc Imaging"},{"key":"R52-20251030","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1016\/j.jcmg.2020.09.023","article-title":"Radionuclide imaging in the diagnosis of transthyretin cardiac amyloidosis.","volume":"14","author":"Rodrigues","year":"2021","journal-title":"JACC Cardiovasc Imaging"}],"container-title":["Cardiology in Review"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/CRD.0000000000001074","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T21:00:30Z","timestamp":1761858030000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/CRD.0000000000001074"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,20]]},"references-count":39,"URL":"https:\/\/doi.org\/10.1097\/crd.0000000000001074","relation":{},"ISSN":["1538-4683"],"issn-type":[{"value":"1538-4683","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,20]]}}}